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Abstract Despite being a favorite delicacy, only 200–300
of the 5,000 known mushroom species have been clearly
established to be safe for consumption. Cases of mushroom
poisoning have been reported with diverse clinical syn-
dromes. A syndromic classification of mushroom poisoning
has recently been developed to facilitate early interventions.
We present a series of five cases of mushroom poisoning
with muscarinic manifestations to highlight the difficulties
we faced with exact species and toxin identification and the
importance of this syndromic classification. The common
symptoms in our case series are blurred vision, diarrhea,
vomiting, and abdominal cramps.
Keywords Mushroompoisoning.Muscarinic.Syndromic
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Introduction
Mushrooms are a favorite delicacy in many parts of the
world, including Malaysia. One of the dominant varieties
cultivated in this part of Southeast Asia is the grey oyster
mushroom (Pleurotus ostreatus)[ 1]. There are an increas-
ing number of toxicology reports [2, 3] resulting from
uncultivated mushroom consumption. Many of these
uncultivated mushroom varieties are the wild types,
ingested because of their physical resemblance to the
known edible varieties [2], while others are ingesting these
foraged varieties for their psychedelic effects [4]. Although
there are as many as 5,000 mushroom species, only 200–
300 varieties have clearly been established to be safe for
consumption, whereas approximately 50–100 types are
known to be poisonous [2]. For the majority of the other
mushroom species, whether they are edible or poisonous
has not been established [2]. In this article, we report a
series of five cases of mushroom poisoning that occurred in
a family.
Case reports
Patient A
Patient A, a 24-year-old farmer, found wild mushrooms
growing in his orchard and plucked them for consumption,
thinking that they appeared similar to some he had eaten
before.
Two hours after consuming the mushrooms, he started to
develop blurred vision, giddiness, and vomited twice prior
to his admission to the emergency department (ED) of the
Hospital Universiti Sains Malaysia.
When he arrived, he was diaphoretic, with drenching
sweats, copious salivation and lacrimation, as well as
crampy abdominal pain (Fig. 1). He vomited twice in the
ED and had one episode of loose stools. Otherwise, his
vital signs were stable. His pupils were measured at 3 mm
bilaterally and were reactive to light. On auscultation of the
lungs, there were coarse crackles up to the mid lung
bilaterally. With his muscarinic syndromic presentation,
intravenous atropine infusion and activated charcoal were
administered.
He was admitted to the general medical ward. Within a
few hours, his secretions and his general condition
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range [aspartate aminotransferase (AST) 31 U/l, alanine
aminotransferas (ALT) 15 U/l, and alkaline phosphatase
(ALP) 36 U/l]. He was discharged after 2 days in the wards.
Patient B
Patient B, a 32-year-old Malay female, was the spouse of
patient A. Like her husband, she started having episodes of
crampy abdominal pain with loose stools and vomiting as
well as blurred vision 2 h after consuming the mushrooms.
She also had profuse sweating, lacrimation, and lung
crepitus. Like her husband, she was also given intravenous
atropine infusion besides activated charcoal. She was
admitted to the general medical ward and discharged at
about the same time as her husband. Her transaminases
remained normal.
Patient C
Patient C was a 32-year-old Malay female, the elder sister
of patient A. She cooked the sliced mushrooms gathered by
her brother by sautéing them. She developed blurred vision
with three episodes of diarrhea and vomiting. She had mild
sweating but no increase in lacrimation. Her lungs were
clear on auscultation. She was given activated charcoal, but
not intravenous atropine. She was monitored in the
observation ward in the ED and was discharged after 6 h
of observation.
Patient D
Patient D was the younger sister of patient C. Like her elder
sister, this 13-year-old Malay female also presented with
two episodes of vomiting and diarrhea as well as mild
sweating. She was given activated charcoal, but not
intravenous atropine. She was discharged symptom-free
after 6 h of observation in the ED.
Patient E
Patient E was the father of patients A, C, and D. He had
blurred vision. Other than that, he had no other symptoms.
He was monitored in the observation ward in the
emergency department, then was well and discharged
home.
A summary of the symptom presentation of all five
patients is given in Table 1.
One of the family members brought some left-over
sliced raw mushroom pieces to us (see Fig. 2). We sent
them for identification to the National Poison Center in
Penang, Malaysia. Unfortunately, the National Poison
Center can only test for a limited number of toxin assays
using gas chromatography with mass spectrometry. The
toxins tested were muscimol, bufotenine, psilocybin, and
gyromitrin - all of which tested negative in our sample. We
attempted to take a second sample from the family’s house;
however, no more similar mushrooms grew in the vicinity.
Furthermore, the sample provided to us was sliced pieces of
raw mushroom wrapped in a clear plastic bag. This could
Table 1 Symptom presentation of the five patients
Patient
A
Patient
B
Patient
C
Patient
D
Patient
E
Blurred vision X X X X X
Diarrhea X X X X –
Vomiting X X X X –
Abdominal cramps X X X X –
Lacrimation X X –––
Salivation X ––––
Fig. 2 The mushroom samples given by the family
Fig. 1 Shows the condition of patient A with drenching sweat
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method of sampling should be to dig up the entire
mushroom in order to preserve the bulb-stem-cap architec-
ture and to transport them in a dry paper bag in their
entirety without crushing or refrigerating them [4]. This
reduces the risk of autolysis of the sample and prevents
discoloration and premature release of spores [4].
One week after patients A and B were discharged from
the ward, we conducted a follow-up telephone interview to
check their general conditions. All of them were well
without any residual symptoms.
Discussion
These cases illustrate the difficulties of exact species and
toxin identification and the importance of the recent
introduction of syndromic classification for mushroom
poisoning.
In 1987, Zilker suggested that the diagnosis of mush-
room poisoning should be based on three principles: the
description of the mushroom, the toxicological analysis of
the mushroom, and, most importantly, the presenting
syndrome [5]. Later on, Blackman, in his review article,
suggested mushroom poisoning can be stratified into seven
clinical profiles [6]. He further recommended a cut-off
point of 6 h in terms of the duration of symptom onset after
ingestion rather than 4 h as suggested by Zilker [5]. This is
because patients who present with symptom onset of more
than 6 h suggest a more serious poisoning due to species
that contain gyromitrin and amanitin as compared to those
that present with a delay of less than 6 h. Many other
classification systems for mushroom poisoning have been
developed over the years [7–9]. However, as shown by the
American Association of Poison Control Center's (AAPCC)
data, problems remain because the exact species and toxins
go unidentified in more than 95% and 90% of the cases,
respectively [4]. This further attests to the difficulties in the
management of mushroom poisoning.
Because of these factors, a recent syndromic classifica-
tion of mushroom poisoning has been developed to
facilitate direct, earlier diagnosis and permit prompt
interventions with specific therapies [4].
Under this syndromic classification, any mushroom
poisoning case is first stratified into three different presen-
tation timings - early onset (less than 6 h), late onset (6-24 h),
and delayed onset (more than 1 day). Under each presenta-
tion timing category, the case is then further stratified into
different predominant organ toxicities. There are eight early
onset syndromes (four neurotoxic, two gastrointestinal, and
two allergic), three late onset syndromes (hepatotoxic,
accelerated nephrotoxic, and erythromelalgia), and finally,
three delayed onset syndromes (delayed nephrotoxic,
delayed neurotoxic, and rhabdomyolysis). The four neuro-
toxic early onset syndromes are cholinergic (the category
where the cases presented here are stratified), glutaminergic,
epileptogenic, and hallucinogenic [4, 10].
Many of the case reports that have been published be-
fore concern late-onset hepatotoxic manifestations due to
Amanita [3, 4] species mushroom poisoning [11, 12]. This
is because the most severe forms of poisoning and fatalities
are usually due to ingestion of mushrooms from this group
[3, 4], except for sporadically reported cases due to other
mushroom groups [13].
In this paper, we highlight five cases of mushroom
poisoning that presented not with hepatotoxic manifesta-
tions, but with muscarinic symptoms. These symptoms
usually occur due to mushroom ingestions of the Inocybe
or Clitocybe species group [14–16]. In our cases, even
though not identified due to the lack of a second sample,
this did not deter us from early implementation of specific
therapies based on the recognition of common signs and
symptoms.
Mushroom poisoning with muscarinic toxidrome can
present with a variety of signs and symptoms that can even
vary among persons who ingested the mushroom grown in
the same patch at the same time. This is clearly illustrated
in the five cases presented in this paper. Therefore, accurate
diagnosis of poisoning due to muscarine-containing mush-
rooms should not depend on the recognition of the species,
but rather on the recognition of the common muscarinic
manifestations, particularly the diaphoresis, salivation,
bladder cramping, diarrhea, and difficulty with visual
accommodation [10, 16]. These typical symptoms were all
seen in all of our patients, especially in patients A and B,
although the most common symptom in our cases was the
transient blurring of vision.
Nevertheless, unlike poisoning due to the Amanita
species, which usually manifests after 6 h, fatalities are
rare with early onset muscarine-containing mushrooms [4,
10]. In 2007, Pauli and Foot described the first ever
reported fatality in Australia due to the ingestion of wild
mushrooms with muscarinic syndrome [13]. In their case, it
was a 53-year-old woman who died 10 h post ingestion of
Rubinoboletus sp., which had not been reported to result in
death in the English language literature before [13]. This
again testifies to the rarity of fatality secondary to ingestion
of muscarine-containing mushrooms.
Treatment of muscarine-containing mushroom poisoning
is mainly supportive, consisting primarily of administration
of activated charcoal [3, 10, 17, 18]. Activated charcoal is
an effective, inert, and nontoxic adsorbant that irreversibly
binds intraluminal toxins and interferes with their absorp-
tion, especially for high molecular weight compounds [17,
18]. To control secretions [10], intravenous atropine is the
treatment of choice [3, 10, 16]. Other than that, no other
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mushroom poisoning [10]. In fact, there is no commonly
available analytical technique to identifiy muscarine in
body fluids [10].
Conclusion
In conclusion, we believe one should not be too preoccu-
pied with the exact identification of species and toxins
before initiating treatment for mushroom poisoning, which
only leads to a delay in treatment. The number of species
and toxins are too numerous, and in many countries like
Malaysia, the number of species and toxins that can be
identified is limited. In this regards, we find that the
syndromic classification of mushroom poisonings is very
useful to facilitate treatment and stratification of cases.
Secondly, as the identification of the different toxidromes in
poisoning can be a very difficult task even for the most
astute and experienced physicians, one should always
maintain a high level of suspicion when handling such
cases [17, 18]. Perhaps the use of a preformatted,
standardized admission chart designed specifically for
poisoning admission would help facilitate clinical assess-
ment, as well as serve as a database for comprehensive
research undertakings in the area of toxicology [19].
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